BR9810409A - Métodos e composições para a modulação de responsividade a corticosteróides - Google Patents

Métodos e composições para a modulação de responsividade a corticosteróides

Info

Publication number
BR9810409A
BR9810409A BR9810409-8A BR9810409A BR9810409A BR 9810409 A BR9810409 A BR 9810409A BR 9810409 A BR9810409 A BR 9810409A BR 9810409 A BR9810409 A BR 9810409A
Authority
BR
Brazil
Prior art keywords
agent
cortecosteroid
individual
methods
preferred
Prior art date
Application number
BR9810409-8A
Other languages
English (en)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9810409A publication Critical patent/BR9810409A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"MéTODOS E COMPOSIçõES PARA A MODULAçãO DE RESPONSIVIDADE A CORTICOSTERóIDES"<D>. Método para modulação de responsividade a cortecosteróides em indivíduos que são providos. No método da invenção, um agente o qual antagoniza um alvo que regula a produção de <B>IFN<D>-y no indivíduo é administrado ao indivíduo na combinacão com um cortecosteroíde de modo que a responsividade do indivíduo ao cortecosteróide é modulada como comparada quando um cortecosteróide sozinho é administrado ao indivíduo. Em uma incorporação, o agente é um antagonista de II-18. Em outra incorporação, o agente é um antagonista de interleucina-12 (IL-12). Em ainda outra incorporação, o agente é um antagonista de célula <B>NK<D>. Em uma incorporação preferida, o agente é um inibidor de uma protease da família de caspase, preferencialmente um inibidor ICE. Em oiutra incorporação preferida, o agente é um anticorpo monoclonal de anti-IL-12. Em ainda outra incorporação preferida, o agente é um anticorpo de anti-asiato-<B>GM-1<D> ou um anticorpo <B>NK1.1.<D> Outros agentes preferidos incluem inibidores fosfodiesterase<B>IV<D> e agonistas beta-2. Os métodos da invenção podem ser usados no tratamento de uma variedade de doenças e distúrbios compreendem um agente o qual antagonista um alvo que regula a produção de <B>IFN<D>-y em um indivíduo, um cortecosteróide e um veículo farmaceuticamente aceitável são também providos. Uma composição preferida compreende um inibidor ICE, um cortecosteróide e um veículo farmaceuticamente aceitável.
BR9810409-8A 1997-03-18 1998-03-12 Métodos e composições para a modulação de responsividade a corticosteróides BR9810409A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (1)

Publication Number Publication Date
BR9810409A true BR9810409A (pt) 2000-08-22

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810409-8A BR9810409A (pt) 1997-03-18 1998-03-12 Métodos e composições para a modulação de responsividade a corticosteróides

Country Status (20)

Country Link
EP (1) EP0998300A1 (pt)
JP (1) JP2002504091A (pt)
KR (1) KR20000076420A (pt)
CN (1) CN1269722A (pt)
AU (1) AU734756B2 (pt)
BG (1) BG103808A (pt)
BR (1) BR9810409A (pt)
CA (1) CA2282845A1 (pt)
DE (1) DE998300T1 (pt)
ES (1) ES2146192T1 (pt)
HU (1) HUP0104439A3 (pt)
ID (1) ID22975A (pt)
IL (1) IL131815A0 (pt)
NO (1) NO994506L (pt)
NZ (1) NZ337769A (pt)
PL (1) PL336464A1 (pt)
SI (1) SI20110A (pt)
SK (1) SK122199A3 (pt)
TR (1) TR199902615T2 (pt)
WO (1) WO1998041232A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
ATE274920T1 (de) * 1997-10-31 2004-09-15 Wyeth Corp Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
WO1999047154A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
CA2355345A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
ES2251248T3 (es) * 1998-12-09 2006-04-16 Protein Design Labs, Inc. Uso de anticuerpos contra il-12 para tratar la psoriasis.
WO2000055114A1 (en) 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
BR0009610A (pt) 1999-04-09 2002-02-13 Cytovia Inc Inibidores de caspase e uso dos mesmos
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
EA200200301A1 (ru) 1999-08-27 2002-08-29 Сайтовиэ, Инк. ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
EP2332579A3 (en) 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
ES2267778T3 (es) * 2000-06-06 2007-03-16 Glaxo Group Limited Composicion para el tratamiento del cancer, que contiene un agente anti-neoplastico y un inhibidor de pde4.
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
UA80676C2 (en) * 2001-01-29 2007-10-25 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy
IL158866A0 (en) * 2001-05-16 2004-05-12 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
CA2461946C (en) * 2001-10-05 2010-01-12 Combinatorx, Incorporated Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2566877A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP5595632B2 (ja) 2004-07-16 2014-09-24 敦生 関山 Ｉｌ−１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
JPWO2006041121A1 (ja) * 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および／または予防剤
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
CA2666612C (en) * 2006-10-17 2012-11-27 Lipothera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
EP2810954A3 (en) 2008-03-18 2015-03-18 Abbvie Inc. Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG190878A1 (en) 2010-11-24 2013-07-31 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
CA3206106A1 (en) 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
JP2024534570A (ja) * 2021-09-22 2024-09-20 イオリクス セラピューティクス，インコーポレーテッド 眼炎症性疾患を処置する方法
WO2024215900A2 (en) * 2023-04-12 2024-10-17 The Board Of Trustees Of The University Of Illinois Agonists of small heterodimer partner for cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
FR2651678B1 (fr) * 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
AU718851B2 (en) * 1995-04-14 2000-04-20 Smithkline Beecham Corporation Metered dose inhaler for beclomethasone dipropionate

Also Published As

Publication number Publication date
TR199902615T2 (xx) 2000-03-21
HUP0104439A2 (hu) 2002-04-29
SI20110A (sl) 2000-06-30
BG103808A (en) 2000-07-31
NZ337769A (en) 2002-09-27
NO994506L (no) 1999-11-17
SK122199A3 (en) 2000-12-11
ES2146192T1 (es) 2000-08-01
PL336464A1 (en) 2000-06-19
DE998300T1 (de) 2001-03-01
CN1269722A (zh) 2000-10-11
AU734756B2 (en) 2001-06-21
HUP0104439A3 (en) 2002-08-28
NO994506D0 (no) 1999-09-17
KR20000076420A (ko) 2000-12-26
WO1998041232A3 (en) 2000-10-05
ID22975A (id) 1999-12-23
AU6760498A (en) 1998-10-12
JP2002504091A (ja) 2002-02-05
WO1998041232A2 (en) 1998-09-24
EP0998300A1 (en) 2000-05-10
IL131815A0 (en) 2001-03-19
CA2282845A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
BR9810409A (pt) Métodos e composições para a modulação de responsividade a corticosteróides
BR9714415A (pt) Heterociclos contendo nitrogênio substituìdo como inibidores de proteìnas quinase p38
BR9911786A (pt) Inibidores heterocìclicos de p38
DE69830404D1 (de) P38-inhibitoren
BR0206985A (pt) Anticorpos modificados e métodos de uso
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
CA2339253A1 (en) Inhibitors of p38
CA2322311A1 (en) Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
ES2136624T3 (es) Implante biocompatible para regular la ovulacion en yeguas.
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
BR9812134A (pt) Composição farmacêutica para tratamento de dismenorréia e parto prematuro
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
GR3031261T3 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy.
IE821828L (en) Blood platelet aggregation inhibitors containing anagrelide
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
BR9608047A (pt) Composição para limpeza à frio à base de alcanos ou cicloalcanos e de um composto orgânico compreendendo uma função cetona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.